Impact of cytokines levels and interleukin 6 (-634 C>G) polymorphism on clinical outcomes in patients with sepsis
Sepsis is the leading cause of death in intensive care units (ICUs), despite increased research on inflammation and the use of new therapies. APACHE II and SOFA prognostic scores, serum levels of certain cytokines, and IL6 (-634 C>G) polymorphisms were evaluated, in association with sepsis and mo...
Saved in:
Published in | Meta Gene Vol. 26; p. 100814 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Elsevier B.V
01.12.2020
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Sepsis is the leading cause of death in intensive care units (ICUs), despite increased research on inflammation and the use of new therapies. APACHE II and SOFA prognostic scores, serum levels of certain cytokines, and IL6 (-634 C>G) polymorphisms were evaluated, in association with sepsis and mortality. Overall, 120 patients (70 septic and 50 non-septic) admitted to the ICU of a cardiology hospital were included in this study. Serum cytokine levels were determined by cytometric bead array and IL6 polymorphisms were evaluated by polymerase chain reaction-restriction fragment length polymorphism analysis. Among the 120 patients and in the group of patients with sepsis, interleukin (IL) 6 demonstrated the highest serum levels. Patients with sepsis showed higher APACHE II and SOFA and greatly elevated IL6 levels. Additionally, both scores were associated with mortality. IL6 polymorphism did not influence the serum levels of this cytokine, prognostic scores, or the risk of sepsis. IL6 levels were associated with sepsis, but a polymorphism minimally investigated in this context, IL6 (-634 C>G), did not influence the serum levels of this interleukin or the clinical outcomes of patients with sepsis. However, as this gene is extremely polymorphic, a broader association study of prognostic scores is needed, considering other polymorphisms. |
---|---|
ISSN: | 2214-5400 2214-5400 |
DOI: | 10.1016/j.mgene.2020.100814 |